Interstitial low-dose-rate brachytherapy as a salvage treatment for recurrent head-and-neck cancers: long-term results
- PMID: 11567809
- DOI: 10.1016/s0360-3016(01)01637-6
Interstitial low-dose-rate brachytherapy as a salvage treatment for recurrent head-and-neck cancers: long-term results
Abstract
Purpose: Recurrent cancers of the head and neck within previously irradiated volume pose a serious therapeutic challenge. This study evaluates the response and long-term tumor control of recurrent head-and-neck cancers treated with interstitial low-dose-rate brachytherapy.
Methods and materials: Between 1979 and 1997, 220 patients with prior radiation therapy with or without surgery for primary tumors of the head and neck were treated for recurrent disease or new primary tumors located within previously irradiated volumes. A majority of these patients had inoperable diseases with no distant metastasis. There were 136 male and 84 female patients, and median age was 56 years. All patients had previously received radiation therapy as the primary treatment or adjuvant treatment following surgery, with a median dose of 57.17 cGy (range, 39-74 cGy). The salvage brachytherapy consisted of a low-dose-rate, afterloading Iridium(192) implant, which delivered a median minimum tumor dose of 53 Gy to a mean tumor volume of 68.75 cm(2). Sixty percent of the patients also received interstitial hyperthermia, and 40% received concurrent chemotherapy as a radiosensitizing and potentiating agent.
Results: At a minimum 6-month follow-up, local tumor control was achieved in 77% (217/282) of the implanted tumor sites. The 2, 5, and 10-year disease-free actuarial survival rates for the entire group were 60%, 33%, and 22%, respectively. The overall survival rate for the entire group at 5 years was 21.7%. Moderate to severe late complications occurred in 27% of the patients.
Conclusion: It has been estimated that approximately 20-30% of head-and-neck cancer patients undergoing definitive radiation therapy have recurrence within the initial treatment volume. Furthermore, similar percentages of patients who survive after successful irradiation develop new primary tumors of the head and neck or experience metastatic neck disease. A majority of such patients cannot be treated with a repeat course of external beam irradiation because of limited normal tissue tolerance, leading to unacceptable morbidity. However, in a select group of these patients, salvage interstitial brachytherapy may play an important role in providing patients with durable palliation and tumor control, as well as a chance for cure.
Similar articles
-
Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer.Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1444-50. doi: 10.1016/j.ijrobp.2004.12.078. Int J Radiat Oncol Biol Phys. 2005. PMID: 16029806
-
Re-irradiation with interstitial pulsed-dose-rate brachytherapy for unresectable recurrent head and neck carcinoma.Brachytherapy. 2014 Mar-Apr;13(2):187-95. doi: 10.1016/j.brachy.2013.10.008. Epub 2013 Nov 6. Brachytherapy. 2014. PMID: 24211123
-
Is there a place for brachytherapy in the salvage treatment of cervical lymph node metastases of head and neck cancers?Brachytherapy. 2015 Nov-Dec;14(6):933-8. doi: 10.1016/j.brachy.2015.07.003. Epub 2015 Aug 3. Brachytherapy. 2015. PMID: 26249122
-
High-dose-rate brachytherapy in the treatment of recurrent and residual head and neck cancer.Laryngoscope. 2002 Aug;112(8 Pt 1):1366-71. doi: 10.1097/00005537-200208000-00008. Laryngoscope. 2002. PMID: 12172246 Review.
-
A review on re-irradiation for recurrent and second primary head and neck cancer.Oral Oncol. 2005 Mar;41(3):225-43. doi: 10.1016/j.oraloncology.2004.07.006. Epub 2004 Nov 23. Oral Oncol. 2005. PMID: 15743686 Review.
Cited by
-
125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region.Strahlenther Onkol. 2013 Jun;189(6):502-7. doi: 10.1007/s00066-013-0324-3. Epub 2013 Apr 28. Strahlenther Onkol. 2013. PMID: 23625361
-
Brachytherapy in head and neck malignancies: Indian Brachytherapy Society (IBS) recommendations and guidelines.J Contemp Brachytherapy. 2020 Oct;12(5):501-511. doi: 10.5114/jcb.2020.100385. Epub 2020 Oct 30. J Contemp Brachytherapy. 2020. PMID: 33299441 Free PMC article.
-
Single institution implementation of permanent 131Cs interstitial brachytherapy for previously irradiated patients with resectable recurrent head and neck carcinoma.J Contemp Brachytherapy. 2019 Jun;11(3):227-234. doi: 10.5114/jcb.2019.85778. Epub 2019 Jun 28. J Contemp Brachytherapy. 2019. PMID: 31435429 Free PMC article.
-
A systematic review of treating recurrent head and neck cancer: a reintroduction of brachytherapy with or without surgery.J Contemp Brachytherapy. 2018 Oct;10(5):454-462. doi: 10.5114/jcb.2018.79399. Epub 2018 Oct 31. J Contemp Brachytherapy. 2018. PMID: 30479623 Free PMC article. Review.
-
Local Control and Toxicity of External Beam Reirradiation With a Pulsed Low-dose-rate Technique.Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):959-964. doi: 10.1016/j.ijrobp.2017.12.012. Epub 2017 Dec 23. Int J Radiat Oncol Biol Phys. 2018. PMID: 29485075 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical